Celgene Stock

CELG

Delayed Nasdaq 04:00:00 2019-11-20 pm EST			5-day change	1st Jan Change
108.24 ^USD	+0.10%		-1.97%	+68.89%

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

News in other languages: Celgene

21-04-07	DGAP-WpÜG: Angebot zum Erwerb / Zielgesellschaft: ; Bieter: qqqqq
21-03-25	Leonteq wird neue Emittentin an der BX Swiss AG im Segment «deriBX»
21-02-02	BX Swiss AG startet Handel in neuem Bondsegment
20-07-07	Die BX Swiss AG erhält von der FINMA die Zulassung zur Führung des Schweizer Beraterregisters
20-07-03	Möbel Markt mömax wird neuer Ankermieter im Rüti Center in Pratteln

More news

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Employees

Sector

More about the company

Market Cap	77.04B 69.14B 63.84B 57.89B 108B 7,317B 110B 765B 304B 3,835B 289B 283B 12,163B	P/E 2017	28.7x	P/E 2018	11.6x
Enterprise Value	91.26B 81.9B 75.63B 68.58B 128B 8,668B 130B 907B 360B 4,543B 343B 335B 14,408B	EV / Sales 2017	6.61x	EV / Sales 2018	3.86x
Free-Float	-	Yield 2017 *	-	Yield 2018	-

23-06-14	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
21-09-07	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI
21-06-21	Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	CI
21-02-22	Celgene Corporation Issues Notice of Redemption of Notes	CI
21-02-04	Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	CI
21-01-04	Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	CI
20-12-22	Amgen : Signs Licensing Agreement With Medicines Development for Global Health	MT
20-11-05	Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	MT
20-09-22	Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	CI
20-09-21	Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	CI
20-03-25	Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	CI
20-03-10	Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	CI
20-03-04	Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	CI

23-02-28	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
22-08-24	Not What The Doctor Ordered: Authorisation Application Withdrawn For Pharma Patent Settlement In Australia	AQ
22-07-29	Authorisation request for proposed settlement between pharmaceutical companies withdrawn	AQ
22-02-24	BRISTOL MYERS SQUIBB CO : Other Events (form 8-K)	AQ
21-08-04	Celgene : Sun Pharma And Celegene Settle Patent Dispute Over Lenalidomide (Revlimid®)	AQ

	2017	2018
Net sales	13B 11.67B 10.78B 9.77B 18.26B 1,235B 18.49B 129B 51.31B 647B 48.81B 47.77B 2,053B	15.28B 13.71B 12.66B 11.48B 21.46B 1,451B 21.73B 152B 60.3B 761B 57.36B 56.13B 2,413B
Net income	2.94B 2.64B 2.44B 2.21B 4.13B 279B 4.18B 29.21B 11.6B 146B 11.04B 10.8B 464B	4.05B 3.63B 3.35B 3.04B 5.68B 384B 5.75B 40.2B 15.97B 201B 15.19B 14.86B 639B
Net Debt	3.79B 3.4B 3.14B 2.85B 5.33B 360B 5.39B 37.69B 14.97B 189B 14.24B 13.93B 599B	14.22B 12.76B 11.79B 10.69B 19.97B 1,351B 20.22B 141B 56.11B 708B 53.38B 52.24B 2,245B

Celgene Stock

Stocks

CELG

Valuation: Celgene

Latest news: Celgene

Press Releases: Celgene

News in other languages: Celgene

Quotes and Performance

Financials

Company Profile